Core Viewpoint - WuXi AppTec's stock price has shown significant growth this year, with a year-to-date increase of 75.56%, despite recent fluctuations in the short term [1][2]. Financial Performance - For the period from January to September 2025, WuXi AppTec achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61% [2]. - The net profit attributable to shareholders for the same period was 12.076 billion yuan, marking an impressive year-on-year increase of 84.84% [2]. Stock Market Activity - As of November 24, WuXi AppTec's stock price was 93.68 yuan per share, with a trading volume of 1.071 billion yuan and a turnover rate of 0.47% [1]. - The company experienced a net inflow of main funds amounting to 46.0942 million yuan, with significant buying and selling activities from large orders [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 274,100, reflecting a growth of 16.39% [2]. - The average number of circulating shares per shareholder remained stable at 9,024 shares [2]. Dividend Distribution - WuXi AppTec has distributed a total of 14.06 billion yuan in dividends since its A-share listing, with 10.406 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the second-largest circulating shareholder, holding 249 million shares, a decrease of 52.6071 million shares from the previous period [3]. - Other notable institutional shareholders, such as Huaxia SSE 50 ETF and Huatai-PB CSI 300 ETF, also reported reductions in their holdings [3].

资料显示，上海南方模式生物科技股份有限公司位于上海市浦东新区琥珀路63弄1号，成立日期2000年9 月20日，上市日期2021年12月28日，公司主营业务涉及从事基因修饰动物模型的研发、生产、销售及相 关技术服务。主营业务收入构成为：标准化模型48.34%，模型技术服务21.92%，模型繁育19.50%，定 制化模型9.34%，其他(补充)0.91%。 南模生物所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：细胞治疗、CRO概 念、抗癌治癌、抗癌药物、增持回购等。 截至9月30日，南模生物股东户数6687.00，较上期增加2.53%；人均流通股11658股，较上期减少 2.47%。2025年1月-9月，南模生物实现营业收入3.03亿元，同比增长14.29%；归母净利润2676.49万元， 同比增长276.14%。 11月24日，南模生物盘中上涨2.09%，截至09:51，报41.45元/股，成交725.80万元，换手率0.23%，总市 值32.32亿元。 南模生物今年以来股价涨79.28%，近5个交易日跌5.24%，近20日跌12.72%，近60日跌30.39%。 今年以来南模生物已经4次 ...

转自：新华财经 科济药业联合创始人、COO王华茂则从产业落地层面介绍了公司的产能建设与生产工艺优化战略。据其介绍，未来将进一步打造涵盖自体与异体CAR-T细 胞制造能力的一体化智能细胞制造中心，预计设计产能将提升至每年数万人份，大幅提升产品供应能力。 "未来我们将聚焦工艺自动化、管理信息化和产业链协同化三大方向，持续降低生产成本、提升产品质量，让CAR-T疗法更易被患者获得。"王华茂强调，科 济药业的最终目标是助力中国CAR-T产业实现"全球领跑"，为更多癌症患者带来治愈希望。 近年来，BD（商务合作与授权）交易数量迎来爆发式增长，此类交易已成为生物制药企业重要的收入来源，这一合作议题也因此成为投资机构关注的焦 点。科济药业回应投资机构表示，BD合作的核心取决于产品竞争力、企业实力及能否满足合作方需求，而非单纯的外部环境因素。科济药业深耕细胞治疗 领域11年，与多家跨国公司（MNC）保持良好合作关系，如今已具备硬核产品、优质平台和稳健现金流的优势。 对于BD策略，科济药业表示其更偏向长期价值导向。"得益于稳健的发展态势，我们无需'卖青苗'求生存，在BD决策上拥有充足的灵活空间。BD工作的核 心目的是为公司发展 ...

Core Insights - Baijin Life Sciences (01466) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity subscription, aiming to establish a leading global circRNA technology R&D platform and enhance innovation in cell therapy [1][2] Group 1: Company Overview - Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. focuses on circRNA technology platform development and innovative drug development, also providing CRO services [2] - The company has successfully obtained U.S. patent authorization for "Circular RNAs and Preparation Methods thereof" and Chinese invention patent authorization for "A Residue-Free Sequence Circular RNA Based on Ribozyme Self-Splicing and Its Preparation Method" [2] Group 2: Collaboration Focus Areas - The initial collaboration will prioritize exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Development of circRNA delivery systems using exosome and cell delivery technologies, leveraging Baijin's exosome and cell platforms [3] - Engineering enhanced exosome and cell drugs for cardiovascular and tissue repair applications, targeting conditions such as myocardial infarction, cerebral infarction, Alzheimer's, and Parkinson's diseases [3] - Development of precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]

智通财经APP讯，佰金生命科学(01466)公布，公司间接全资附属公司北京佰金生物科技有限公司(北京 佰金)与优环(苏州)生物医药科技有限公司(优环生物)签订策略合作框架协议，据此，北京佰金将透过认 购优环生物股权的方式对优环生物进行投资，旨在打造全球领先的环状RNA(circ RNA)技术研发平台并 借助此平台，深化细胞治疗领域的技术创新。订约方尚未确定相关投资的实际时间及金额。合作框架协 议将于2026年12月31日届满，协议任何一方均可提前10天通知另一方提前终止合作框架协议。 据悉，优环(苏州)生物医药科技有限公司是一家聚焦于circ RNA技术平台研发与创新药物开发并兼具 CRO服务(即医药合同研发机构服务)的双驱动生物医药企业，自主管线研发的同时，包括circ RNA设计 的全流程CRO服务。公司自主研发的"Circular RNAs and Preparation Methods thereof(circ RNA及其制备 方法)"成功获得美国专利授权;"一种基于核酶自剪接的无残留序列环状RNA及其制备方法"成功获得中 国发明专利授权;且正与国际前沿药物研发领域大型企业开展深度合作，并在某细胞应用 ...

格隆汇11月19日丨佰金生命科学(01466.HK)公布，公司间接全资附属公司北京佰金生物科技有限公司 ("北京佰金")与优环(苏州)生物医药科技有限公司("优环生物")签订策略合作框架协议，据此，北京佰金 将透过认购优环生物股权的方式对优环生物进行投资，旨在打造全球领先的环状RNA(circRNA)技术研 发平台并借助此平台，深化细胞治疗领域的技术创新。订约方尚未确定相关投资的实际时间及金额。合 作框架协议将于2026年12月31日届满，协议任何一方均可提前10天通知另一方提前终止合作框架协议。 优环(苏州)生物医药科技有限公司是一家聚焦于circ RNA技术平台研发与创新药物开发并兼具CRO服务 (即医药合同研发机构服务)的双驱动生物医药企业，自主管线研发的同时，包括circ RNA设计的全流程 CRO服务。公司自主研发的「Circular RNAs and Preparation Methodsthereof(circ RNA及其制备方法)」成 功获得美国专利授权；「一种基于核酶自剪接的无残留序列环状RNA及其制备方法」成功获得中国发 明专利授权；且正与国际前沿药物研发领域大型企业开展深度合作，并在某细 ...

Core Insights - WuXi AppTec's stock price increased by 2.03% on November 19, reaching 94.19 CNY per share, with a trading volume of 1.279 billion CNY and a market capitalization of 281.04 billion CNY [1] - The company has seen a year-to-date stock price increase of 76.52%, with a recent 5-day increase of 1.99%, a 20-day decrease of 6.65%, and a 60-day increase of 4.76% [1] - For the first nine months of 2025, WuXi AppTec reported revenue of 32.857 billion CNY, a year-on-year growth of 18.61%, and a net profit attributable to shareholders of 12.076 billion CNY, reflecting an 84.84% increase [2] Financial Performance - The company's main business revenue composition includes: chemical business 78.37%, testing services 12.93%, biological services 6.02%, and other services 1.90% [1] - WuXi AppTec has distributed a total of 14.06 billion CNY in dividends since its A-share listing, with 10.406 billion CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 274,100, a rise of 16.39% from the previous period, with an average of 9,024 circulating shares per person [2] - Major shareholders include Hong Kong Central Clearing Limited, holding 249 million shares, and various ETFs, with some reducing their holdings [3]

据了解，此次论坛上共发布十项新锐成果，覆盖肿瘤、心脑血管、感染性疾病等重大领域，融合AI赋 能研发、细胞治疗、干细胞技术等前沿方向，充分展现了深圳作为国家生物医药创新先行尖兵的产业实 力，以及"AI赋能，向新而行"的发展特色。 其中，两项成果来自深圳理工大学，分别是器官衰竭阻断药物AS1501和TrkB小分子激动剂BrAD-R13。 由深圳理工大学药学院院长、欧洲科学院院士陈有海团队联合深圳市中科艾深医药有限公司研发的 AS1501，是全球首款基于TRAIL-DR5通路阻断剂方向的生物创新药，为肝损伤、肝衰竭等重症治疗带 来革命性突破。目前，AS1501针对肝损伤、肝衰竭的研究已进入临床Ⅱ期，远超同类国际竞品的临床 前研究阶段，在全球范围内无直接竞争对手。作为器官衰竭阻断领域的全新突破，该药物不仅为肝衰、 心梗等重症患者提供了新的治疗选择，更彰显了我国在原创生物药研发领域从"跟跑"向"领跑"的跨越。 南都讯 记者伍曼娜 通讯员李韵 11月15日，在深圳理工大学主办的第二十七届高交会院士论坛——深圳 创新药发展论坛上，深圳市2025年创新药新锐成果正式发布。 由深圳理工大学生命健康学院院长叶克强团队联合深圳博芮 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.963 billion yuan for the first three quarters of 2025, a year-on-year increase of 2.15%, and a net profit attributable to the parent company of 551 million yuan, a year-on-year decrease of 6.48%. In Q3 2025 alone, the revenue was 670 million yuan, a year-on-year increase of 7.7%, and the net profit was 185 million yuan, a year-on-year increase of 6.56% [4][5] - The company's main business has stabilized and is showing signs of recovery, with positive growth in both revenue and profit in Q3, primarily driven by the growth in revenue from growth hormones and antibody drugs. The decline in profit for the first three quarters is attributed to increased R&D investment, which reached 145 million yuan, a year-on-year increase of 13.08% [5] - The company has successfully introduced two significant long-acting products through business development (BD) collaborations, enhancing its market position in the fields of pediatric growth and assisted reproduction [6] - The company’s affiliate, Bosheng Jian, has made significant progress in its cell therapy platform, with the CD7 CAR-T (PA3-17 injection) being included as a breakthrough therapy and approved for key Phase II clinical trials [7] Financial Summary - The company expects revenues for 2025, 2026, and 2027 to be 2.677 billion yuan, 3.050 billion yuan, and 3.529 billion yuan, respectively, with year-on-year growth rates of 5.6%, 13.9%, and 15.7%. The net profit attributable to the parent company is projected to be 756 million yuan, 848 million yuan, and 987 million yuan for the same years, with year-on-year growth rates of 6.9%, 12.1%, and 16.4% [8][9] - Key financial metrics for 2025 include a gross margin of 78.4%, a return on equity (ROE) of 17.4%, and earnings per share (EPS) of 0.45 yuan [11]

Group 1 - The core viewpoint of the news is that 恒瑞医药's stock has experienced fluctuations, with a recent decline of 2.00% and a year-to-date increase of 34.88% [1] - As of November 17, the stock price is reported at 61.64 CNY per share, with a total market capitalization of 409.12 billion CNY [1] - The company has seen a net outflow of 1.92 million CNY in principal funds, with significant selling pressure observed [1] Group 2 - 恒瑞医药, established on April 28, 1997, focuses on the research, production, and sales of pharmaceuticals, particularly in the oncology field [2] - The company's main revenue sources are product sales (86.88%), licensing income (12.63%), and other income (0.49%) [2] - The company operates in various therapeutic areas, including oncology, pain management, and cardiovascular diseases [2] Group 3 - As of September 30, the number of shareholders has increased to 397,300, while the average circulating shares per person have decreased by 8.21% [3] - For the period from January to September 2025, 恒瑞医药 reported a revenue of 23.188 billion CNY, reflecting a year-on-year growth of 14.85%, and a net profit of 5.751 billion CNY, up 24.50% year-on-year [3] Group 4 - Since its A-share listing, 恒瑞医药 has distributed a total of 9.303 billion CNY in dividends, with 3.568 billion CNY distributed in the last three years [4] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 487 million shares, a decrease of 48.179 million shares from the previous period [4] - Other notable shareholders include China Securities Finance Corporation and various ETFs, with some experiencing a reduction in shareholding [4]